Breast cancer life expectancy: Statistics and outcomes
- Medical Review: Douglas Yee, MD
If you’ve been diagnosed with breast cancer and you’re concerned about how long you’ll live, you’re not alone. Even if doctors say, “your situation looks good,” many people worry about life expectancy after a cancer diagnosis.
A number of factors go into a general picture of how long someone might live after a breast cancer diagnosis. These include how far the cancer has spread, how the cancer is behaving, how well the treatment is working, health status before diagnosis, age, and more. And when you're looking for answers, a survival statistic might seem like dependable information.
However, statistics are not personalized to your specific situation. Statistics help researchers understand how breast cancer affects large groups of people, not any individual person. Average percentages often reflect thousands of people in research done years ago — but never just one person, today.
While we can generally say that someone with stage 0 breast cancer has a better survival rate than someone with stage IV breast cancer, we can also say that people being diagnosed with breast cancer right now may have better survival rates than current numbers show. That's because it takes time to track and record survival rates, and these numbers are often a few years behind new advances in treatment.
The American Cancer Society reports that U.S. breast cancer death rates decreased by 43% between 1989 and 2020. Research shows that this is likely the result of advances in breast cancer treatment. According to the ACS, breast cancer screening and awareness also play a role.
Here are the American Cancer Society's latest relative survival rates:
Relative survival rates for U.S. women diagnosed with breast cancer
- 91% at 5 years post-diagnosis
- 84% after 10 years
- 80% after 15 years
Source: American Cancer Society, Breast Cancer Facts & Figures, 2022-2024
On this page, we'll help you understand how survival rates are estimated and different ways that survival rates are tracked, including by age, race and ethnicity, gender, stage, and subtype.
It's important to remember that your situation could be very different than what is shown in the numbers on this page. If you have concerns about how long you'll live, talk with your healthcare team about the individual factors that contribute to your overall life picture.
How survival rate is estimated
Survival rates for all cancers are estimated by looking at data on large numbers of people who have a certain type of cancer. Researchers gather information about the people over periods of time, such as five years, 20 years, or longer.
Living Beyond Breast Cancer, like the American Cancer Society, uses U.S. survival rates based on data from the Surveillance, Epidemiology, and End Results Program, known as SEER, of the National Cancer Institute (NCI). The NCI works with the North American Association of Central Cancer Registries to gather this information from every state in the U.S. on an ongoing basis.
For breast cancer, the SEER database uses five-year relative survival rates. A five-year relative survival rate is the number of people likely to be alive five years after a breast cancer diagnosis, not including people who die from other diseases.
For example, if a certain stage of breast cancer has a five-year relative survival rate of 90%, it means that on average, people diagnosed with that cancer are about 90% as likely to live at least five years post-diagnosis as people not diagnosed with that cancer.
Survival rates can help your medical team get a better understanding of your prognosis: the likely course of the breast cancer. Following people for at least five years is an important part of survival rate calculations.
Survival rate by stage
Stage is an important factor in determining the prognosis of cancer, because in general, the higher the stage, the lower the five-year survival rate. Below is a table showing the five-year relative survival rate for localized, regional, and distant breast cancer. These categories are defined as follows:
- Localized breast cancer is invasive cancer found only in the breast. It does not include ductal carcinoma in situ (DCIS).
- Regional breast cancer is invasive cancer that spreads to nearby parts of the body, such as the chest wall or lymph nodes.
- Distant breast cancer is invasive cancer that spreads to other parts of the body, such as the lungs, liver, bones, and brain.
SEER stage | 5-year relative survival rate |
---|---|
Localized | 99% |
Regional | 86% |
Distant | 30% |
All SEER stages combined | 91% |
*These rates are based on women who were diagnosed between 2012 and 2018.
It’s important to know that the survival rate for your type of breast cancer may be different than what’s represented in this chart. Here are some reasons why:
- The numbers in the chart above represent women diagnosed and treated many years ago. As treatments improve, survival rate numbers can change.
- These numbers also do not factor in certain cancer characteristics such as grade, hormone receptor status, or HER2 status.
- These numbers also don’t consider age or overall health.
- These numbers also don’t consider how well a cancer treatment may work in your body.
- These numbers do not include the approval of new drugs that have affected survival rates.
Survival rates by demographics
Breast cancer survival rates and mortality numbers are different depending on the group of people being studied. Survival-related demographics tracked in the SEER breast cancer database include age, race and ethnicity, and gender. Below, we present different survival rates from the SEER Explorer tool.
Survival rates by age
Researchers look at breast cancer statistics across demographics such as age. Keep in mind that just like the survival rates appearing earlier on this page, the numbers reflected in this table are averages.
Breast cancer 5-year relative survival rates by age and stage at diagnosis (women, all races) 2013-2019
All ages | Ages <50 | Ages 50-64 | Ages 65+ | |
---|---|---|---|---|
Stage at diagnosis | % surviving | % surviving | % surviving | % surviving |
Localized | 99.3 | 97.4 | 98.7 | 100.0 |
Regional | 86.3 | 87.8 | 87.8 | 83.3 |
Distant | 31.0 | 41.7 | 32.1 | 25.0 |
While these numbers provide a broad look at survival by age and stage, there are details that were not considered here. For instance, we know that women aged 45 and under are more likely to be diagnosed with biologically aggressive breast cancers, and this has a negative impact on prognosis. However, the factors that provide this information, including cancer grade, whether a person has an inherited high-risk gene mutation, or test results that show a high risk for recurrence, were not part of the information gathered for this table.
For more specific information about metastatic (stage IV) breast cancer survival rates, visit Stage IV breast cancer prognosis.
Survival rates by breast cancer subtype
Below are tables showing the five-year relative survival rates by age and stage at diagnosis for the four most common subtypes of breast cancer. Remember that every breast cancer case is unique, and that the numbers presented here are averages calculated from a large group of people over a long period of time. They may not represent your experience. If you have questions, it’s okay to take statistics to your care team and ask them to help you understand more.
If you’re interested in seeing more data on breast cancer survival and trends, this tool provided by SEER can be useful.
HR+/HER2- breast cancer five-year relative survival rates by age and stage at diagnosis (women, all races) 2013-2019
All ages | Ages <50 | Ages 50-64 | Ages 65+ | |
---|---|---|---|---|
Stage at diagnosis | % surviving | % surviving | % surviving | % surviving |
Localized | 100.0 | 98.6 | 99.7 | 100.0 |
Regional | 90.3 | 91.2 | 91.3 | 88.5 |
Distant | 34.0 | 42.3 | 33.7 | 30.7 |
HER2-/HR+ breast cancer five-year relative survival rates by age and stage at diagnosis (women, all races) 2013-2019
All ages | Ages <50 | Ages 50-64 | Ages 65+ | |
---|---|---|---|---|
Stage at diagnosis | % surviving | % surviving | % surviving | % surviving |
Localized | 97.2 | 96.8 | 97.5 | 96.6 |
Regional | 84.0 | 87.1 | 85.9 | 76.8 |
Distant | 39.5 | 49.0 | 40.3 | 29.0 |
Triple-negative breast cancer five-year relative survival rates by age and stage at diagnosis (women, all races) 2013-2019
All ages | Ages <50 | Ages 50-64 | Ages 65+ | |
---|---|---|---|---|
Stage at diagnosis | % surviving | % surviving | % surviving | % surviving |
Localized | 91.8 | 91.0 | 92.5 | 91.6 |
Regional | 66.2 | 67.7 | 68.4 | 61.5 |
Distant | 12.8 | 16.4 | 13.0 | 10.2 |
Triple-positive breast cancer five-year relative survival rates by age and stage at diagnosis (women, all races) 2013-2019
All ages | Ages <50 | Ages 50-64 | Ages 65+ | |
---|---|---|---|---|
Stage at diagnosis | % surviving | % surviving | % surviving | % surviving |
Localized | 99.1 | 98.4 | 99.0 | 99.8 |
Regional | 89.8 | 93.4 | 90.6 | 83.3 |
Distant | 45.6 | 57.8 | 46.3 | 34.7 |
Survival rates and mortality numbers by race and ethnicity
Another way that researchers track survival by demographic is by gathering information about survival in different racial groups. Just like the numbers above, the numbers shown here are averages that did not consider every factor that impacts survival.
Source: American Cancer Society, Breast Cancer Facts & Figures, 2022-2024
U.S. breast cancer mortality numbers in women, by race and ethnicity, 2016-2020
Race/Ethnicity | Number of deaths per 100,000 women |
---|---|
White | 19.7 |
Black | 27.6 |
Asian/Pacific Islander | 11.7 |
American Indian/Alaska Native (total U.S.) | 20.5 |
Hispanic | 13.7 |
We know that survival rates for Black women are different than they are for white women. Black women are 40% more likely to die of breast cancer than white women. This disparity exists in part due to differences in tumor biology, but also because of socioeconomic inequality that demands change.
- Black women are more likely to be diagnosed with triple-negative breast cancer, which often means a poorer prognosis than with other subtypes of breast cancer in the first five years after diagnosis.
- Socioeconomic disparity also affects survival rates. Some of these disparities lead to decreased access to preventive care, lack of adequate health insurance, and inadequate or disparate treatment from healthcare providers. LBBC is committed to empowering our community to advocate for health equity through educational programs, sharing the stories of Black women, and more.
However, whether a woman was faced with socioeconomic challenges or had triple-negative breast cancer was not looked at when the researchers gathered these numbers.
Survival rates by gender
SEER also tracks survival rates by male and female gender.
Five-year relative survival rates for male and female breast cancer (2013-2019)
Male | Female | |
---|---|---|
Stage at diagnosis | % surviving | % surviving |
Localized | 95.3 | 99.3 |
Regional | 85.9 | 86.3 |
Distant | 25.6 | 31.0 |
Looking at statistics can feel like we’re getting a clearer view of a cancer’s prognosis. But it’s important to remember that some factors aren’t reflected in averages. Two people of the same age, gender, and ethnicity can be diagnosed with the same subtype of breast cancer and have very different outcomes; often, doctors don’t know why this happens. A person’s income, place of residence, diet, lifestyle, past or ongoing medical issues, and how their body responds to cancer treatment all impact their individual survival outcome. This page is not a crystal ball. On the day you’re reading this page, many factors that influenced the numbers reported here, including what cancer treatments are available to you, may have changed.
What does all of this mean for you? Since these numbers do not capture important details that can make your individual situation very different than someone else’s, it’s important to have a conversation with your doctor if you’re concerned about life expectancy. This is about the whole you: not just the characteristics of the cancer, but many other factors too. You’re more than a number. You’re a whole human being, and each person diagnosed with breast cancer has a unique picture of their prognosis.
Rate of diagnosis
The breast cancer incidence rate in the United States, which describes how many cases of breast cancer are diagnosed each year, has increased each year for many years. But a rising incidence rate does not necessarily mean that more people are developing breast cancer. It can also mean that more people are being diagnosed due to new and better diagnostic techniques. For example, in the 1980s and 1990s, annual mammograms became much more common. Data show that during those decades, many more people were diagnosed with breast cancer.
At first glance, it can seem like a bad thing to have more people diagnosed with breast cancer. But with increased screening like mammograms, cancers are being found at earlier stages than cancers diagnosed after symptoms start. Cancers found at earlier stages are often smaller and easier to treat.
The chart below shows the rate of breast cancer incidence and declining mortality in U.S. women over 45 years.
Source: American Cancer Society, Breast Cancer Facts & Figures, 2022-2024
Coping with your prognosis
Even if your healthcare team has told you that your prognosis is very good, it’s normal to feel worried sometimes about how long you’ll live. Fear of recurrence or cancer progression is extremely common after a diagnosis.
If you’re dealing with anxiety or overwhelmed about your prognosis, you’re not alone, and we’re here for you. Visit our page on coping with a new breast cancer diagnosis for information and tips on navigating different emotions and finding support.
The importance of screening
If you’ve been diagnosed with breast cancer, and especially if you have a higher risk due to a hereditary gene mutation or other factors, screening can mean earlier detection of a recurrence or new breast cancer. Regular breast cancer screenings, including mammograms, have been shown to reduce the risk of dying from breast cancer and increase survival rates. Talk with your healthcare team about the screening plan that’s best for you.
Additional resources
Stay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.
- 3-dimensional radiation therapy
- 4-hydroxytamoxifen
- ablation
- abnormal
- Abraxane
- absolute risk
- AC regimen
- AC-T regimen
- AC-T-T regimen
- AC-Taxol regimen
- AC-TH regimen
- accelerated partial-breast irradiation
- action study
- acupoint
- acupressure
- acupuncture
- acupuncture needle
- acupuncture point
- acupuncture point injection
- acupuncturist
- acustimulation
- acute
- acute pain
- adenocarcinoma
- adenopathy
- adenosis
- adjunct agent
- adjunct therapy
- adjunctive therapy
- adjuvant therapy
- advance directive
- advanced practice nurse
- adverse effect
- aerobic exercise
- agent study
- aggravating factor
- aggressive
- AJCC staging system
- Alkeran
- alkylating agent
- Allegra
- allopathic medicine
- alopecia
- amifostine
- aminoglutethimide
- amitriptyline
- anabolic steroid
- analgesic
- anaplastic
- anastrozole
- ancillary test
- anemia
- anesthesia
- anesthesiologist
- angiogenesis
- angiogenesis inhibitor
- antagonist
- anthracycline
- anti-anxiety medicine
- anti-idiotype vaccine
- anti-inflammatory
- antibody-dependent cellular cytotoxicity
- antibody therapy
- anticachexia
- anticancer antibiotic
- anticancer therapy
- anticonvulsant
- antidepressant
- antiemetic
- antiestrogen
- antifolate
- antigen-presenting cell vaccine
- antihormone therapy
- antimetabolite
- antimitotic agent
- antineoplastic
- antitumor
- anxiety
- anxiolytic
- Anzemet
- APN
- apocrine gland
- apoptosis
- aprepitant
- areola
- Aromasin
- aromatase inhibitor
- aromatherapy
- arthralgia
- ascites
- aspirate
- aspiration
- assay
- asthenia
- asymptomatic
- atypia
- atypical ductal hyperplasia
- atypical hyperplasia
- atypical lobular hyperplasia
- avoidance
- axillary lymph node
- axillary lymph node dissection
- BAK gel
- balloon catheter radiation
- baseline
- behavior modification
- best practice
- BI-RADS
- Biafine cream
- bias
- bilateral
- bilateral breast cancer
- bilateral prophylactic mastectomy
- bilateral salpingo-oophorectomy
- biofeedback
- biologic
- biopsy
- biopsy specimen
- biotherapy
- bisphosphonate
- bisphosphonate-associated osteonecrosis
- blinded study
- blood-brain barrier
- blood-brain barrier disruption
- blood cell count
- blood chemistry study
- board certified oncology pharmacy specialist
- body image
- body mass index
- bolus dose
- bone density
- bone metastasis
- bone mineral density scan
- bone scan
- bone-seeking radioisotope
- brachytherapy
- brain metastasis
- BRCA1
- BRCA2
- BRCAPro
- breast carcinoma in situ
- breast-conserving surgery
- breast density
- breast duct
- breast duct endoscopy
- breast lobe
- breast lobule
- breast reconstruction
- breast self-exam
- Brief Pain Inventory
- cachexia
- CAF regimen
- calcification
- cancer vaccine
- candidiasis
- capecitabine
- carboplatin
- carcinogen
- carcinoma
- carcinoma in situ
- carcinomatous meningitis
- carcinosis
- carcinostatic
- cardiotoxicity
- caregiver
- carmustine
- case-control study
- case report
- case series
- CAT scan
- CBC
- cell
- cell-cycle regulation
- cell proliferation
- central nervous system
- central nervous system metastasis
- central nervous system prophylaxis
- central venous access catheter
- cetuximab
- cevimeline
- chaplain
- charged-particle radiation therapy
- chemoembolization
- chemoimmunotherapy
- chemoprevention
- chemoprevention study
- chemoprotective
- chemoradiation
- chemosensitivity
- chemosensitivity assay
- chemosensitizer
- chemotherapeutic agent
- chemotherapy
- chest wall
- chest X-ray
- Chinese meridian theory
- chronic
- chronic pain
- cisplatin
- Claus model
- clergy
- clinical
- clinical breast exam
- clinical practice guidelines
- clinical researcher
- clinical resistance
- clinical series
- clinical stage
- clinical staging
- clinical study
- clinical trial
- clinician
- clodronate
- CMF regimen
- cognition
- cognitive behavior therapy
- cognitive therapy
- cohort
- cohort study
- coinsurance
- combination chemotherapy
- comedo carcinoma
- comfort care
- Coming Out
- Community Advisory Board
- comorbidity
- compassionate use trial
- complementary and alternative medicine
- complementary medicine
- complete metastasectomy
- complete remission
- complete response
- complex decongestive therapy
- compliance
- complication
- compression garment
- computed tomography scan
- concomitant
- concurrent therapy
- condition
- consolidation therapy
- constitutional acupuncture
- continuum of care
- contract research organization
- contraindication
- contralateral
- contrast material
- control group
- controlled clinical trial
- controlled study
- conventional medicine
- conventional therapy
- copayments
- cope
- coping skills
- core biopsy
- core needle biopsy
- corticosteroid
- counseling
- COX inhibitor
- cryoablation
- cryopreservation
- cryosurgery
- CT scan
- cultural competency
- cumulative dose
- cumulative exposure
- cure
- cutaneous
- cutaneous breast cancer
- cyclophosphamide
- cyclosporine
- CYP2D6 inhibitor
- cystosarcoma phyllodes
- cytopenia
- cytotoxic
- cytotoxic chemotherapy
- Cytoxan
- Data and Safety Monitoring Board
- DCIS
- de novo
- debulking
- deductible
- definitive surgery
- definitive treatment
- dehydration
- denosumab
- depression
- diagnosis
- diagnostic mammogram
- diagnostic procedure
- diagnostic technique
- diagnostic trial
- diameter
- diarrhea
- diaziquone
- DIEP flap
- dietary counseling
- dietary supplement
- dietitian
- differentiation
- diffuse
- digital mammography
- diphenhydramine
- discharge
- disease progression
- disease-specific survival rate
- distant cancer
- distant metastasis
- Distant recurrence
- distress
- DNR order
- docetaxel
- dolasetron
- dose
- dose-dense chemotherapy
- dose-dependent
- dose-limiting
- dose-rate
- double-blinded
- doxorubicin
- drain
- dronabinol
- droperidol
- drug interaction
- drug resistance
- drug therapy
- drug tolerance
- duct
- ductal carcinoma
- ductal carcinoma in situ
- ductal lavage
- duloxetine
- durable power of attorney
- dysfunction
- dysgeusia
- dyspepsia
- dyspnea
- early menopause
- early-stage breast cancer
- edema
- EEG biofeedback
- efficacy
- Eklund displacement views
- electroacupuncture
- electron beam
- eligibility criteria
- Ellence
- emesis
- emetic
- endocrine
- endocrine therapy
- endpoint
- energy healing
- enteral nutrition
- epidemiology
- epirubicin
- ER+
- ER-
- ER
- ER-PR-HER2/neu-
- eribulin mesylate
- erythema
- estradiol
- estrogen
- estrogen blocker
- estrogen receptor
- estrogen receptor-negative
- estrogen receptor-positive
- estrogen receptor test
- estrogen replacement therapy
- etanidazole
- etidronate
- everolimus
- Evista
- excision
- excisional biopsy
- exemestane
- expanded access trial
- experimental
- extranodal
- false-negative test result
- false-positive test result
- familial cancer
- family medical history
- Faslodex
- fast-neutron beam radiation
- fatigue
- FDA
- febrile neutropenia
- FEC regimen
- Femara
- fertility
- fexofenadine
- fibroadenoma
- fibrocystic breast changes
- fiducial marker
- film mammography
- fine-needle aspiration biopsy
- first-degree relative
- first-line therapy
- five-year survival rate
- fluorouracil
- fluoxetine
- FNA biopsy
- focal
- Food and Drug Administration
- Fosamax
- fractionation
- fulvestrant
- functional magnetic resonance imaging
- gadolinium
- Gail model
- gallium scan
- gamma irradiation
- Gamma Knife therapy
- gamma ray
- Gelclair
- gemcitabine
- gene
- gene expression profile
- gene therapy
- general anesthesia
- generalized anxiety disorder
- generic
- genetic
- genetic counseling
- genetic marker
- genetic marker of susceptibility
- genetic predisposition
- genetic profile
- genetic susceptibility
- genetic testing
- genetic testing
- genetics
- genome
- genome-wide association study
- genomic profile
- genomic test
- genomics
- gland
- Good Clinical Practice
- goserelin
- grade
- grading
- granisetron
- gross description
- Halaven
- hazard ratio
- healing touch
- Health Insurance Portability and Accountability Act
- healthcare provider
- healthcare proxy
- healthy control
- helical computed tomography
- HER2/neu
- Herceptin
- hereditary
- hereditary mutation
- heteronormative
- high-dose chemotherapy
- high-dose radiation
- high-energy proton therapy
- high grade
- high-risk cancer
- HIPPA
- histologic examination
- histology
- historic cohort study
- historical control subject
- homeopathic medicine
- hormonal therapy
- hormone
- hormone receptor
- hormone receptor test
- hormone replacement therapy
- hormone responsive
- hormone therapy
- hospice
- hot flash
- human epidermal growth factor receptor 2
- human participant protection regulations
- hydroxydaunorubicin
- hyperalimentation
- hypercalcemia
- hyperfractionated radiation therapy
- hyperfractionation
- hyperplasia
- hypersensitivity
- hypofractionated radiation therapy
- hypofractionation
- hypoxia
- ibandronate
- ibuprofen
- idiopathic
- image-guided radiation therapy
- imaging
- imaging procedure
- immune adjuvant
- immune function
- immune response
- immune system
- immune system tolerance
- immunization
- immunoassay
- immunocompromised
- immunodeficiency
- immunohistochemistry
- immunology
- immunomodulation
- immunosuppression
- immunotherapy
- implant
- implant displacement views
- implant radiation therapy
- implantable pump
- in network
- in situ
- incidence
- incision
- incisional biopsy
- indication
- indolent
- induction therapy
- infection
- infertile
- infertility
- infiltrating breast cancer
- infiltrating ductal carcinoma
- inflammation
- inflammatory breast cancer
- informed consent
- infusion
- ingestion
- inherited
- iniparib
- injection
- inoperable
- insomnia
- Institutional Review Board
- intensification therapy
- intensity-modulated radiation therapy
- interfering thought
- internal mammary lymph nodes
- internal radiation therapy
- International Unit
- internist
- interstitial radiation therapy
- intervention
- intervention group
- intra-arterial
- intracarotid infusion
- intradermal
- intraductal breast papilloma
- intraductal carcinoma
- intrahepatic
- intrahepatic infusion
- intramuscular
- intramuscular injection
- intraoperative radiation therapy
- intraoperative ultrasound
- intratumoral
- intravasation
- intravenous
- intravenous infusion
- intravenous injection
- intrusive thought
- intrusive thoughts
- invasive breast cancer
- invasive cancer
- invasive procedure
- investigational
- investigator
- ionizing radiation
- ipsilateral
- IRB
- irradiated
- irradiation
- irreversible toxicity
- ixabepilone
- joint pain
- Karnofsky Performance Status
- laboratory test
- lapatinib
- laser
- laser surgery
- laser therapy
- lassitude
- late effects
- late-stage cancer
- latent
- laxative
- LEEP
- legal aid organization
- lesion
- lethargy
- letrozole
- leukopenia
- levels of evidence
- Lexapro
- libido
- lidocaine
- ligation
- linac
- linear accelerator
- lipoma
- lisofylline
- liver metastasis
- liver scan
- living will
- lobaplatin
- lobe
- lobectomy
- lobular carcinoma
- lobular carcinoma in situ
- lobule
- local anesthesia
- local cancer
- local therapy
- localization
- localized
- locally advanced cancer
- locally recurrent cancer
- lomustine
- loop electrosurgical excision procedure
- loop excision
- lorazepam
- low grade
- lubricant
- lumbar puncture
- lumpectomy
- lung metastasis
- luteinizing hormone-releasing hormone agonist
- lymph
- lymph gland
- lymph node
- lymph node dissection
- lymph node drainage
- lymph node mapping
- lymph vessel
- lymphadenectomy
- lymphadenopathy
- lymphangiogram
- lymphangiography
- lymphatic basin
- lymphatic fluid
- lymphatic mapping
- lymphatic system
- lymphatic vessel
- lymphedema
- lymphography
- lymphoscintigraphy
- Lyrica
- lytic lesion
- macrocalcification
- magnetic resonance imaging
- magnetic resonance perfusion imaging
- magnetic resonance spectroscopic imaging
- mainstream medicine
- maintenance therapy
- male breast cancer
- malignancy
- malignant
- malignant pleural effusion
- malnutrition
- mammary
- mammary dysplasia
- mammary gland
- mammogram
- mammography
- MammoSite
- Mammotome
- mantle field
- MAO inhibitor
- margin
- marker
- mass
- massage therapy
- mastectomy
- mastitis
- maternal
- maximum tolerated dose
- mean survival time
- measurable disease
- medial supraclavicular lymph node
- median
- median survival time
- Medicaid
- medical castration
- medical device
- medical nutrition therapy
- medical oncologist
- Medicare
- medicine
- medullary breast carcinoma
- mega-voltage linear accelerator
- megestrol
- melphalan
- meningeal metastasis
- menopause
- menorrhagia
- menstrual cycle
- menstrual period
- menstruation
- mental health
- mental health counselor
- meridian
- mesna
- meta-analysis
- metallic
- metastasectomy
- metastasis
- metastasize
- metastatic
- methotrexate
- metoclopramide
- metronomic therapy
- microcalcification
- micrometastasis
- microscopic
- milk duct
- mind/body exercise
- mindfulness relaxation
- Miraluma test
- mitigate
- modified radical mastectomy
- molecular marker
- molecular medicine
- molecular risk assessment
- molecularly targeted therapy
- monoamine oxidase inhibitor
- monoclonal antibody
- morbidity
- mortality
- MRI
- MRSI
- MTD
- mTOR
- mucositis
- multicenter study
- multicentric breast cancer
- multidisciplinary
- multidisciplinary opinion
- multidrug resistance
- multidrug resistance inhibition
- multifocal breast cancer
- music therapy
- mutation
- mutation carrier
- myalgia
- myelosuppression
- nanoparticle paclitaxel
- narcotic
- National Cancer Institute
- National Center for Complementary and Alternative Medicine
- National Institutes of Health
- natural history study
- naturopathy
- nausea
- NCCAM
- NCI
- NCI clinical trials cooperative group
- needle biopsy
- needle localization
- needle-localized biopsy
- negative axillary lymph node
- negative test result
- neoadjuvant therapy
- neoplasm
- nerve
- nerve block
- neurocognitive
- neurologic
- neuropathy
- neurotoxicity
- neurotoxin
- neutropenia
- NIH
- nipple
- nipple discharge
- nitrosourea
- NMRI
- node-negative
- node-positive
- nodule
- nonblinded
- nonconsecutive case series
- noninvasive
- nonmalignant
- nonmetastatic
- nonprescription
- nonrandomized clinical trial
- nonsteroidal anti-inflammatory drug
- nonsteroidal aromatase inhibitor
- nontoxic
- normal range
- normative
- NP
- NPO
- NSAID
- nuclear grade
- nuclear magnetic resonance imaging
- nuclear medicine scan
- nurse
- nurse practitioner
- nutrition
- nutrition therapy
- nutritional counseling
- nutritional status
- nutritional supplement
- nutritionist
- obese
- objective improvement
- objective response
- observation
- observational study
- obstruction
- off-label
- olaparib
- oncologist
- oncology
- oncology nurse
- oncology pharmacy specialist
- oncolysis
- ondansetron
- onset of action
- oophorectomy
- open biopsy
- open label study
- open resection
- operable
- opiate
- opioid
- opportunistic infection
- oral
- organ
- orthodox medicine
- osteolytic
- osteonecrosis of the jaw
- osteopenia
- osteoporosis
- OTC
- out of network
- outcome
- outpatient
- ovarian
- ovarian ablation
- ovarian cancer
- ovarian suppression
- ovary
- over-the-counter
- overall survival rate
- overdose
- overexpress
- overweight
- ovulation
- PA
- paclitaxel
- paclitaxel albumin-stabilized nanoparticle formulation
- paclitaxel-loaded polymeric micelle
- Paget disease of the nipple
- pain threshold
- palliation
- palliative care
- palliative therapy
- palmar-plantar erythrodysesthesia
- palonosetron hydrochloride
- palpable disease
- palpation
- palpitation
- pamidronate
- panic
- papillary tumor
- Paraplatin
- parenteral nutrition
- paroxetine hydrochloride
- PARP
- PARP inhibitor
- partial-breast irradiation
- partial mastectomy
- partial oophorectomy
- partial remission or partial response
- pastoral counselor
- paternal
- pathologic fracture
- pathological stage
- pathological staging
- pathologist
- pathology report
- patient advocate
- Paxil
- peau d'orange
- pedigree
- peer-review process
- peer-reviewed scientific journal
- perfusion magnetic resonance imaging
- perimenopausal
- periodic neutropenia
- perioperative
- peripheral neuropathy
- peripheral venous catheter
- personal health record
- personal medical history
- personalized medicine
- Pertuzumab
- PET scan
- pharmacist
- phase I/II trial
- phase I trial
- phase II/III trial
- phase II trial
- phase III trial
- phase IV trial
- phlebotomy
- photon beam radiation therapy
- phyllodes tumor
- physical examination
- physical therapist
- physical therapy
- physician
- physician assistant
- physiologic
- PI3 kinase inhibitor
- pilocarpine
- pilot study
- placebo
- placebo-controlled
- plastic surgeon
- plastic surgery
- population study
- positive axillary lymph node
- positive test result
- positron emission tomography scan
- post-traumatic stress disorder
- postmenopausal
- postoperative
- postremission therapy
- potentiation
- power of attorney
- PR
- PR+
- PR-
- practitioner
- preauthorization
- precancerous
- preclinical study
- predictive factor
- pregabalin
- premalignant
- premature menopause
- premenopausal
- premium
- prescription
- prevention
- preventive
- preventive mastectomy
- primary care
- primary care doctor
- primary endpoint
- primary therapy
- primary treatment
- primary tumor
- Principal investigator
- prochlorperazine
- progesterone
- progesterone receptor
- progesterone receptor-negative
- progesterone receptor-positive
- progesterone receptor test
- progestin
- prognosis
- prognostic factor
- progression
- progression-free survival
- progressive disease
- Prolia
- proliferative index
- promegapoietin
- prophylactic
- prophylactic mastectomy
- prophylactic oophorectomy
- prophylactic surgery
- prophylaxis
- prospective
- prospective cohort study
- prosthesis
- protective factor
- protein
- protein-bound paclitaxel
- protein expression
- protein expression profile
- protocol
- proton
- proton magnetic resonance spectroscopic imaging
- pruritus
- psychiatrist
- psychological
- psychologist
- psychosocial
- psychotherapy
- PTSD
- pump
- punch biopsy
- qi
- qigong
- quadrantectomy
- quality assurance
- quality of life
- radiation
- radiation brachytherapy
- radiation dermatitis
- radiation fibrosis
- radiation necrosis
- radiation nurse
- radiation oncologist
- radiation physicist
- radiation surgery
- radiation therapist
- radiation therapy
- radical lymph node dissection
- radical mastectomy
- radioactive
- radioactive drug
- radioactive seed
- radioisotope
- radiologic exam
- radiologist
- radiology
- radionuclide
- radionuclide scanning
- radiopharmaceutical
- radiosensitization
- radiosensitizer
- radiosurgery
- radiotherapy
- raloxifene
- raloxifene hydrochloride
- randomization
- randomized clinical trial
- receptor
- RECIST
- reconstructive surgeon
- reconstructive surgery
- recreational therapy
- recurrence
- recurrent cancer
- referral
- reflexology
- refractory
- refractory cancer
- regimen
- regional
- regional anesthesia
- regional cancer
- regional chemotherapy
- regional lymph node
- regional lymph node dissection
- registered dietician
- regression
- rehabilitation
- rehabilitation specialist
- relapse
- relative survival rate
- relaxation technique
- remission
- remission induction therapy
- remote brachytherapy
- research nurse
- research study
- resectable
- resected
- resection
- residual disease
- resistant cancer
- resorption
- respite care
- response rate
- retrospective cohort study
- retrospective study
- risk factor
- Rubex
- salpingo-oophorectomy
- salvage therapy
- samarium 153
- sargramostim
- scalpel
- scan
- scanner
- scintigraphy
- scintimammography
- sclerosing adenosis
- screening
- screening mammogram
- second-line therapy
- second-look surgery
- second primary cancer
- secondary cancer
- secrete
- sedative
- segmental mastectomy
- selection bias
- selective estrogen receptor modulator
- selective serotonin reuptake inhibitor
- sentinel lymph node
- sentinel lymph node biopsy
- sentinel lymph node mapping
- sepsis
- sequential AC/Taxol-Trastuzumab regimen
- sequential treatment
- SERM
- sertraline
- Serzone
- sestamibi breast imaging
- sexuality
- sibling
- side effect
- silicone
- simple mastectomy
- simulation
- Single-agent therapy
- sleep disorder
- social service
- social support
- social worker
- sodium thiosulfate
- soft tissue
- solid tumor
- somatic
- somatic mutation
- sorafenib
- specialist
- specificity
- spiculated mass
- spinal anesthesia
- spinal block
- spiral CT scan
- spirituality
- sporadic cancer
- SSRI
- stable disease
- stage
- stage 0 breast carcinoma in situ
- stage 0 disease
- stage I breast cancer
- stage IA breast cancer
- stage IB breast cancer
- stage II breast cancer
- stage II breast cancer
- stage IIA breast cancer
- stage IIB breast cancer
- stage III breast cancer
- stage III lymphedema
- stage IIIA breast cancer
- stage IIIB breast cancer
- stage IIIC breast cancer
- stage IV breast cancer
- staging
- stamina
- standard of care
- standard therapy
- statistically significant
- stent
- stereotactic biopsy
- stereotactic radiosurgery
- sterile
- sternum
- steroid
- stress
- strontium
- study agent
- subcutaneous
- subcutaneous port
- subjective improvement
- subset analysis
- supplemental nutrition
- supplementation
- support group
- supportive care
- supraclavicular lymph node
- surgeon
- surgery
- surgical biopsy
- surgical menopause
- surgical oncologist
- survival rate
- symptom
- symptom management
- symptomatic
- synergistic
- synthetic
- syringe
- systemic
- systemic chemotherapy
- systemic disease
- systemic therapy
- TAC regimen
- tai chi
- tailored intervention
- talk therapy
- tamoxifen
- targeted therapy
- taxane
- Taxol
- Taxotere
- Tc 99m sulfur colloid
- technician
- terminal disease
- therapeutic
- therapeutic touch
- therapy
- thermography
- thiethylperazine
- thiotepa
- third-line therapy
- thrush
- time to progression
- tinnitus
- tissue
- tissue flap reconstruction
- TNM staging system
- tomography
- tomotherapy
- topical
- topical chemotherapy
- topoisomerase inhibitor
- total estrogen blockade
- total mastectomy
- total nodal irradiation
- total parenteral nutrition
- toxic
- toxicity
- tracer
- traditional acupuncture
- tranquilizer
- transdermal
- transfusion
- transitional care
- translational research
- trastuzumab
- trauma
- treatment field
- trigger
- trigger point acupuncture
- triple-negative breast cancer
- tumescent mastectomy
- tumor
- tumor antigen vaccine
- tumor board review
- tumor burden
- tumor debulking
- tumor load
- tumor marker
- tumor volume
- Tykerb
- ulcer
- ulceration
- ultrasound-guided biopsy
- ultrasound/ultrasonography
- ultraviolet radiation therapy
- uncontrolled study
- undifferentiated
- unilateral
- unilateral salpingo-oophorectomy
- unresectable
- unresected
- upstaging
- urticaria
- VACB
- vaccine therapy
- vacuum-assisted biopsy or vacuum-assisted core biopsy
- Valium
- vancomycin
- vandetanib
- vascular endothelial growth factor-antisense oligonucleotide
- vascular endothelial growth factor receptor tyrosine kinase inhibitor
- vein
- Velban
- venipuncture
- venous sampling
- Versed
- vertebroplasty
- vinorelbine
- vital
- vomit
- watchful waiting
- wedge resection
- Wellcovorin
- Western medicine
- WGA study
- white blood cell
- whole cell vaccine
- whole genome association study
- wide local excision
- wire localization
- wound
- X-ray therapy
- Xanax
- Xeloda
- xerostomia
- Xgeva
- yoga
- ziconotide
- Zinecard
- Zofran
- zoledronic acid
- Zoloft
- Zometa
Living Beyond Breast Cancer is a national nonprofit organization that seeks to create a world that understands there is more than one way to have breast cancer. To fulfill its mission of providing trusted information and a community of support to those impacted by the disease, Living Beyond Breast Cancer offers on-demand emotional, practical, and evidence-based content. For over 30 years, the organization has remained committed to creating a culture of acceptance — where sharing the diversity of the lived experience of breast cancer fosters self-advocacy and hope. For more information, learn more about our programs and services.